TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 18 to 60 years on the day of inclusion.~* Informed consent form signed.~* Able to attend all scheduled visits and to comply with all trial procedures.~* For a woman, inability to bear a child or negative urine pregnancy test at the first visit.~Exclusion Criteria :~* Systemic hypersensitivity to egg proteins, chick proteins, or any of the vaccine components, in particular, neomycin, formaldehyde, and octoxinol 9, or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances.~* Febrile illness (oral temperature \>= 37.5°C, or rectal equivalent temperature \>= 38.0°C) on the day of inclusion.~* Participation in another clinical trial in the 4 weeks preceding the trial vaccination.~* Planned participation in another clinical trial during the present trial period.~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.~* Unstable chronic illness (defined as illness requiring hospitalization or a clinically significant change in medication in the 12 weeks prior to inclusion) at a stage that could interfere with trial conduct or completion.~* Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures.~* Blood or blood-derived products received in the past 3 months.~* Any vaccination in the 4 weeks preceding the trial vaccination.~* Vaccination planned in the 4 weeks following the trial vaccination.~* Previous vaccination against influenza (in the previous 6 months).~* Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination.~* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Lot 1
- 2 (Type: EXPERIMENTAL): Lot 2
- 3 (Type: EXPERIMENTAL): Lot 3
- 4 (Type: ACTIVE_COMPARATOR): Control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neuroimaging of Anesthetic Modulation of Human Consciousness

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have a body mass index (BMI) less than 30.~2. Must be right handed~3. Must be English speaking~4. Must be capable of giving written informed consent.~5. Must have history of playing tennis (or any type of racquet sport) at least 30 times over lifetime.~Exclusion Criteria:~1. History of obstructive sleep apnea;~2. History of a difficult airway with a previous anesthetic;~3. History of neurological disorders;~4. Hypertension or other cardiovascular abnormalities;~5. Pulmonary hypertension or other pulmonary abnormalities;~6. Gastroesophageal reflux disease (GERD) or heartburn;~7. History of significant head injury with loss of consciousness;~8. Learning disability or other developmental disorder;~9. Allergic reactions to eggs;~10. Pregnant or nursing mothers;~11. Contraindications to neuroimaging methods;~12. Inability or unwilling to fast, or withhold food and liquid intake, for 8 hours prior to your scheduled study visit.~13. Unwilling to abstain from alcohol use for 24 hours prior to your scheduled study visit.~14. History of drug use, or have a positive drug screen.~15. Tattoos on the head or neck region - all other tattoos are subject to determination by investigators.~16. Any impairment, activity or situation that in the judgment of the study coordinator or Principal Investigators would prevent satisfactory completion of the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Propofol Administration (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognition Intervention Study Dortmund

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All sixth grade students of Gesamtschule Berger Feld with the consent of parents and child~Exclusion Criteria:~* Metabolic diseases or special diet

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Having lunch/skipping lunch (Type: EXPERIMENTAL): Lunch ad libitum on test day 1 and no lunch on test day 2. Water available on both days.
- Skipping lunch/having lunch (Type: EXPERIMENTAL): No lunch on test day 1 and lunch ad libitum on test day 2. Water available on both days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have documented atrial fibrillation on 2 separate occasions within 6 months before screening~* History of a prior stroke, transient ischemic attack or non-neurologic systemic embolism believed to be cardiac in origin, or at least two of the following risk factors: heart failure, hypertension, age 75 years or greater, diabetes mellitus~Exclusion Criteria:~* Significant mitral stenosis~* Transient atrial fibrillation caused by a reversible disorder~* Active internal bleeding~* Severe disabling stroke~* History of intracranial bleeding~* Hemorrhagic disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): None
- Warfarin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Serotonin, Impulsivity, and Cocaine Dependence Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* male and female subjects age 18 to 50 who currently meet DSM-IV criteria for cocaine dependence.~* female subjects: a negative pregnancy test~Exclusion Criteria:~* current or past DSM-IV Axis I disorder other than substance abuse/dependence~* any serious non-psychiatric medical illness requiring ongoing medical treatment~* substance dependence other than cocaine within the last 3 months~* negative urine drug screen for cocaine at time of testing~* for female subjects: a positive pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female children who completed the previous four dose vaccination series study (NCT00129129). The age of the child at the 3 post-fourth dose timelines are as follows:~  * Year 1: 22 to 36 months of age.~ * Year 3: 44 to 60 months of age.~ * Year 5: 5 years post-dose 4 +/- 8 weeks~* Written informed consent obtained from the parent or guardian of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study~* Having completed the fourth dose vaccination of study Hib-MenCY-TT-005/006~Exclusion Criteria:~Children should not have:~* received more than 4 doses of Hib or meningococcal serogroup C and Y vaccine~* had a history of H. influenzae type b, meningococcal serogroup C and Y diseases

- Gender: ALL
- Minimum Age: 22 Months
- Maximum Age: 60 Months
- Healthy Volunteers: t

Study Arms:
- MenHibrix 4-dose group (Type: EXPERIMENTAL): Subjects received in the primary study (NCT00129129) 3 doses of MenHibrix co-administered with Pediarix and Prevnar and a 4th dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
- ActHIB 4-dose group (Type: ACTIVE_COMPARATOR): Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a 4th dose of ActHIB co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
- ActHIB 3-dose + MenHibrix 4th-dose group (Type: EXPERIMENTAL): Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Outcome of Vascular Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Ages 60+~2. DSM-IV criteria for MDD~3. Hamilton Depression Rating Scale score \>18~4. No MRI contraindications, e.g. foreign metallic implants, pacemaker~5. Medication free of any psychotropic drug except as otherwise noted for set washout period (see D.2.1)~6. Mini Mental Status Exam score \<21~7. No unstable medical disorders (requiring immediate medical attention)~8. Ability to give informed consent~9. English speaking~Exclusion Criteria:~1. Age \<60~2. Does not meet DSM-IV criteria for MDD~3. Hamilton Depression Rating Scale score \<18~4. MRI contraindications e.g. foreign metallic implants, pacemaker~5. Psychotropic drug use other than zolpidem and lorazepam, prn within 2 weeks of entry~6. Mini Mental Status Exam score \>21, or known primary neurological disorders including Dementia of the Alzheimer type, Parkinson's Disease, multiple sclerosis, seizure disorder.~7. Unstable medical disorders, uncorrected hypothyroidism, or any condition that in the investigators opinion makes the patients unsuitable for a trial~8. Cannot give informed consent~9. Does not speak English

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1) At least 18 years old~* 2) Have had a positive culture (a type of test) for MRSA during recent hospital admission or within the 30 days prior to admission or following discharge~* 3) Able to give consent or have a primary caregiver provide consent~* 4) Able to bathe or shower or have this consistently performed by a willing caregiver~Exclusion Criteria:~* 1) Known allergies to chlorhexidine or mupirocin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRSA Decolonization (Type: ACTIVE_COMPARATOR): Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
- Education Arm (Type: ACTIVE_COMPARATOR): Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nitroglycerin Infusion During Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* elective cardiac surgery~Exclusion Criteria:~* heart failure, respiratory failure, asthma attack, uremia, normothermic bypass.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- High-dose NTG (Type: EXPERIMENTAL): Nitroglycerin infusion 1-5 mcg/kg/min
- Low-dose NTG (Type: ACTIVE_COMPARATOR): Nitroglycerin infusion 0-0.1 mcg/kg/min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults, \>/=18 years of age~* metastatic melanoma, stage IIIC or IV (AJCC)~* treatment-naïve (no prior systemic anticancer therapy)~* positive for BRAF V600E mutation~* measurable disease by RECIST criteria~* negative pregnancy test and, for fertile men and women, effective contraception during treatment and for 6 months after completion~Exclusion Criteria:~* active central nervous system metastases~* history of carcinomatous meningitis~* severe cardiovascular disease within 6 months prior to study drug administration~* previous malignancy within 5 years prior to study, except for basal or squamous cell carcinoma of the skin, melanoma in-situ, or carcinoma in-situ of the cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vemurafenib (Type: EXPERIMENTAL): None
- Dacarbazine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage I-IVB squamous cell carcinoma of the nasopharynx~  * WHO I-III~ * No stage IVC disease~ * No evidence of distant metastasis~* Measurable or evaluable disease~* Must have been treated with primary radiotherapy~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-1~Life expectancy~* Not specified~Hematopoietic~* White blood cell count (WBC) at least 4,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* Not specified~Renal~* Creatinine no greater than 1.6 mg/dL~* Creatinine clearance at least 60 mL/min~Other~* Not pregnant (If stage T2b or greater or node-positive disease)~* Negative pregnancy test (If stage T2b or greater or node-positive disease)~* No other prior head and neck cancer~* No other malignancy within the past 5 years except nonmelanoma skin cancer~* No active untreated infection~* No other major medical or psychiatric illness that would preclude study entry~* Nutritional and general physical condition compatible with radiotherapy NOTE: \*If stage T2b or greater or node-positive disease~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* More than 6 months since prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~* More than 6 months since prior radiotherapy for head and neck cancer~Surgery~* No prior head and neck surgery to the primary tumor or lymph nodes except incisional or excisional biopsies~Other~* No other concurrent experimental therapy for cancer~* No amifostine or pilocarpine during or for 3 months after radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMRT +/- chemotherapy (Type: EXPERIMENTAL): Intensity modulated radiation therapy (IMRT) for all patients and chemotherapy (cisplatin and fluorouracil) for patients with stage ≥ T2b and/or N+

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 6 months overactive bladder symptoms, minimum of 2 urgency urinary incontinence episodes per 24 hours and minimum of 8 micturitions per 24 hours.~Exclusion Criteria:~* Other concurrent and concomitant medication or disease that could put the subjects at additional risk or interfere with the study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fesoterodine 8mg (Type: EXPERIMENTAL): None
- Fesoterodine 4mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Methane in Glycemic Control

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years old with pre-diabetes (hemoglobin a1c of 5.7-6.4%)~* BMI \> 25.0~* presence of methane on a breath sample (\>3ppm)~Exclusion Criteria:~Subjects will be excluded from the study if they exhibit any of the following:~* Diabetes/diabetes medications~* Prokinetic medication~* Pregnancy~* History of bariatric or intestinal surgery (other than cholecystectomy or appendectomy)~* Unstable thyroid disease~* An active weight loss treatment/plan~* Smoking~* Dietary restrictions (lactose intolerance, vegan etc)~* Other inability to comply with the study procedures, including known allergy to the study antibiotics (neomycin and rifaximin)~* Active inflammatory bowel disease (celiac, Crohn's disease, ulcerative colitis)~* Antibiotic use in the past month~* Subjects who do not have a microwave (for reheating study meals) and a freezer (for storing leftovers and stool samples) will be excluded from this study.~* Subjects who have an aspirin sensitivity~* Proton pump inhibitor medications or antacids~* History of bezoar~* Disorders of swallowing~* Suspected strictures, fistulas or physiological GI obstruction~* GI surgery within 3 months~* Severe dysphagia to food or pills~* Diverticulitis~* Subjects who use an implanted or portable electromechanical device such as a cardiac pacemaker or infusion pump~* Subject who have a peanut allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Obese/overweight, prediabetic methane positive (Type: EXPERIMENTAL): Neomycin Rifaximin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete